Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thromboembolism Clear all
Recruiting Early Phase 1 Interventional

Supplemental Oxygen in Pulmonary Embolism (SO-PE)

NCT05891886
View directory record Official record
Conditions
Pulmonary Embolism, Venous Thromboembolism, Metabolomics, Oxygen Inhalation Therapy
Interventions
Oxygen Therapy, Non-rebreather mask
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Jul 22, 2026, 12:55 AM EDT
Not listed Not applicable Interventional

SToP: Venous Thromboembolism Screening in the Trauma Population

NCT02978950
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Trauma, Multiple
Interventions
Duplex ultrasound surveillance, No ultrasound surveillance
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Jul 22, 2026, 12:55 AM EDT
Completed No phase listed Observational

Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events

NCT02155491
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Not listed
Lead sponsor
Thrombosis Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
10,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Muscle Shoals, Alabama
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Jul 22, 2026, 12:55 AM EDT
Suspended Not applicable Interventional

CLEANer Aspiration for Pulmonary Embolism

NCT06189313
View directory record Official record
Conditions
Pulmonary Embolism, Acute Pulmonary Embolism, Cardiovascular Diseases, Venous Thromboembolism
Interventions
Cleaner Pro Thrombectomy System
Device
Lead sponsor
Argon Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 22, 2026, 12:55 AM EDT
Withdrawn Phase 2 Interventional

Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli

NCT02378623
View directory record Official record
Conditions
Patent Foramen Ovale, Cardiac Implantable Electronic Device
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Jul 22, 2026, 12:55 AM EDT
Recruiting Phase 4 Interventional

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

NCT07189897
View directory record Official record
Conditions
Venous Thromboembolism, Head and Neck Cancer
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Kiranya Arnold
Other
Eligibility
18 Years to 89 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jul 22, 2026, 12:55 AM EDT
Completed Phase 3 Interventional Results available

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

NCT02064439
View directory record Official record
Conditions
Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism
Interventions
BAY 59-7939, ASA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Beverly Hills, California • La Jolla, California • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Jul 22, 2026, 12:55 AM EDT
Completed Phase 4 Interventional Results available

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

NCT00966277
View directory record Official record
Conditions
Pancreatic Cancer, Venous Thromboembolism
Interventions
Dalteparin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2016 · Synced Jul 22, 2026, 12:55 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

NCT00680186
View directory record Official record
Conditions
Thromboembolism
Interventions
Warfarin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Jul 22, 2026, 12:55 AM EDT
Completed Not applicable Interventional Results available

AMPLATZER Cardiac Plug Clinical Trial

NCT01118299
View directory record Official record
Conditions
Atrial Fibrillation, Ischemic Stroke, Peripheral Thromboembolism
Interventions
AMPLATZER Cardiac Plug
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • Littleton, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Jul 22, 2026, 12:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

NCT00291330
View directory record Official record
Conditions
Thromboembolism
Interventions
dabigatran etexilate 150 mg, warfarin (INR 2-3)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
23
States / cities
Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Jul 22, 2026, 12:55 AM EDT
Terminated No phase listed Observational Results available

A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

NCT05966740
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
3 Months to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
La Jolla, California • San Diego, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 12:55 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

NCT00876915
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
dalteparin injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Sacramento, California • Buffalo, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Jul 22, 2026, 12:55 AM EDT
Completed No phase listed Observational

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

NCT03521908
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Jul 22, 2026, 12:55 AM EDT
Completed No phase listed Observational

Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data

NCT05264168
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism, DVT
Interventions
Rivaroxaban, Apixaban
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
41,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 22, 2026, 12:55 AM EDT
Completed No phase listed Observational Results available

FlowTriever All-Comer Registry for Patient Safety and Hemodynamics

NCT03761173
View directory record Official record
Conditions
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
Interventions
FlowTriever System, Anticoagulation Agents
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 22, 2026, 12:55 AM EDT
Terminated Not applicable Interventional Results available

Angel® Catheter Early Feasibility Clinical Study

NCT01847196
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
Interventions
Angel® Catheter
Device
Lead sponsor
BiO2 Medical
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Jackson, Mississippi • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Jul 22, 2026, 12:55 AM EDT
Active, not recruiting No phase listed Observational

Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events

NCT06855394
View directory record Official record
Conditions
Atherosclerotic Vascular Disease, Coronary Arterial Disease (CAD), Atherosclerosis of Coronary Artery, Atherosclerosis of Arteries of the Extremities, Unspecified, Heart Diseases, Stroke, Venous Thromboembolic Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
13,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 22, 2026, 12:55 AM EDT
Recruiting Not applicable Interventional

AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.

NCT06939803
View directory record Official record
Conditions
Venothromboembolism
Interventions
Risk model-driven CDS
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
2,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 22, 2026, 12:55 AM EDT
Completed Phase 3 Interventional Results available

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

NCT00986154
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
Interventions
edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
8,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
82
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jul 22, 2026, 12:55 AM EDT
Completed Phase 3 Interventional Results available

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

NCT00571649
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
8,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jul 22, 2026, 12:55 AM EDT
Terminated Not applicable Interventional Results available

Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)

NCT03465735
View directory record Official record
Conditions
Acute DVT of Lower Extremity
Interventions
Vascular Boot, Standard of Care
Combination Product · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jul 22, 2026, 12:55 AM EDT
Terminated Phase 3 Interventional

Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism

NCT01164046
View directory record Official record
Conditions
Venous Thromboembolism, Neoplasms
Interventions
low molecular weight heparin, vitamin K antagonists
Drug
Lead sponsor
University Medical Center Groningen
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Jul 22, 2026, 12:55 AM EDT
Completed Phase 2 Interventional

Preventing Recurrence of Thromboembolic Events Through Coordinated Treatment in the District of Columbia

NCT00703274
View directory record Official record
Conditions
Stroke
Interventions
PROTECT DC
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Jul 22, 2026, 12:55 AM EDT